tetano
Editor, Senior Moderator
J Infect Dis
. 2021 Feb 3;223(2):197-205.
doi: 10.1093/infdis/jiaa618.
Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Katharine H D Crawford[SUP] 1 2 3 [/SUP], Adam S Dingens[SUP] 1 [/SUP], Rachel Eguia[SUP] 1 [/SUP], Caitlin R Wolf[SUP] 4 [/SUP], Naomi Wilcox[SUP] 4 [/SUP], Jennifer K Logue[SUP] 4 [/SUP], Kiel Shuey[SUP] 4 [/SUP], Amanda M Casto[SUP] 4 [/SUP], Brooke Fiala[SUP] 5 6 [/SUP], Samuel Wrenn[SUP] 5 6 [/SUP], Deleah Pettie[SUP] 5 6 [/SUP], Neil P King[SUP] 5 6 [/SUP], Alexander L Greninger[SUP] 7 8 [/SUP], Helen Y Chu[SUP] 4 [/SUP], Jesse D Bloom[SUP] 1 2 9 [/SUP]
Affiliations
Abstract
Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop neutralizing antibodies that target the viral spike protein. In this study, we quantified how levels of these antibodies change in the months after SARS-CoV-2 infection by examining longitudinal samples collected approximately 30-152 days after symptom onset from a prospective cohort of 32 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers declined an average of about 4-fold from 1 to 4 months after symptom onset. This decline in neutralizing antibody titers was accompanied by a decline in total antibodies capable of binding the viral spike protein or its receptor-binding domain. Importantly, our data are consistent with the expected early immune response to viral infection, where an initial peak in antibody levels is followed by a decline to a lower plateau. Additional studies of long-lived B cells and antibody titers over longer time frames are necessary to determine the durability of immunity to SARS-CoV-2.
Keywords: COVID-19; RBD; SARS-CoV-2; antibody dynamics; neutralizing antibodies; spike.
. 2021 Feb 3;223(2):197-205.
doi: 10.1093/infdis/jiaa618.
Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Katharine H D Crawford[SUP] 1 2 3 [/SUP], Adam S Dingens[SUP] 1 [/SUP], Rachel Eguia[SUP] 1 [/SUP], Caitlin R Wolf[SUP] 4 [/SUP], Naomi Wilcox[SUP] 4 [/SUP], Jennifer K Logue[SUP] 4 [/SUP], Kiel Shuey[SUP] 4 [/SUP], Amanda M Casto[SUP] 4 [/SUP], Brooke Fiala[SUP] 5 6 [/SUP], Samuel Wrenn[SUP] 5 6 [/SUP], Deleah Pettie[SUP] 5 6 [/SUP], Neil P King[SUP] 5 6 [/SUP], Alexander L Greninger[SUP] 7 8 [/SUP], Helen Y Chu[SUP] 4 [/SUP], Jesse D Bloom[SUP] 1 2 9 [/SUP]
Affiliations
- PMID: 33535236
- DOI: 10.1093/infdis/jiaa618
Abstract
Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop neutralizing antibodies that target the viral spike protein. In this study, we quantified how levels of these antibodies change in the months after SARS-CoV-2 infection by examining longitudinal samples collected approximately 30-152 days after symptom onset from a prospective cohort of 32 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers declined an average of about 4-fold from 1 to 4 months after symptom onset. This decline in neutralizing antibody titers was accompanied by a decline in total antibodies capable of binding the viral spike protein or its receptor-binding domain. Importantly, our data are consistent with the expected early immune response to viral infection, where an initial peak in antibody levels is followed by a decline to a lower plateau. Additional studies of long-lived B cells and antibody titers over longer time frames are necessary to determine the durability of immunity to SARS-CoV-2.
Keywords: COVID-19; RBD; SARS-CoV-2; antibody dynamics; neutralizing antibodies; spike.